Calixar Overview

  • Founded
  • 2011
  • Status
  • Private
  • Employees
  • 14
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $2.75M
Latest Deal Amount
  • Investors
  • 9

Calixar General Information


Operator of a biotechnology company intended to preserve the original structure and function of membrane protein operations. The company engages in the production, extraction, stabilization, purification, and crystallization of functional membrane proteins and antigens, by isolating them in a native conformation without mutations or deletions, enabling biotechnology companies to develop conformational antibodies and formulate new vaccines efficiently.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Laboratory Services (Healthcare)
Primary Office
  • Bâtiment Laennec
  • 60A Avenue Rockefeller
  • 69008 Lyon
  • France
+33 04 00 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Calixar Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 13-Mar-2020 $2.75M 00.000 Completed Generating Revenue
4. Early Stage VC (Series A) 24-Feb-2015 00.000 00.000 00.000 Completed Generating Revenue
3. Secondary Transaction - Private 17-Oct-2014 00.00 Completed Generating Revenue
2. Early Stage VC (Series A) 18-Jun-2012 $1.1M $1.1M 00.000 Completed Generating Revenue
1. Early Stage VC 01-Jan-2011 Completed Startup
To view Calixar’s complete valuation and funding history, request access »

Calixar Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Class A Preference 00,000 00.000000 000.00 000.00 00 000.00 00.000
Ordinary 0,000 00.000000 000.00 000.00 00 000.00 0.000
Class A Preference 33,400 $1.134983 $28.37 $28.37 1x $28.37 28.17%
To view Calixar’s complete cap table history, request access »

Calixar Patents

Calixar Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201601895-D0 Method for the synthesis of steroidic calixarene compounds, and their use for extraction, solubilization and/or stabilzation of native and functional membrane Ceased 03-Feb-2016 0000000000
US-10144917-B2 Method for preparing a vaccine antigen, resulting vaccine antigen and uses Active 29-Aug-2014 000000000
CA-2959153-A1 Method for preparing a vaccine antigen, resulting vaccine antigen and uses Pending 29-Aug-2014 000000000
JP-2017531032-A Method for producing vaccine antigen, resulting vaccine antigen, and use Pending 29-Aug-2014 000000000
US-20170362578-A1 Method for preparing a vaccine antigen, resulting vaccine antigen and uses Granted 29-Aug-2014 A61K39/12
To view Calixar’s complete patent history, request access »

Calixar Executive Team (5)

Name Title Board Seat Contact Info
Emmanuel Dejean Ph.D Co-Founder, Chairman, President and Chief Executive Officer
Pierre Falson Co-Founder & Scientific Advisor
You’re viewing 2 of 5 executive team members. Get the full list »

Calixar Board Members (1)

Name Representing Role Since
Emmanuel Dejean Ph.D Calixar Co-Founder, Chairman, President and Chief Executive Officer 000 0000
To view Calixar’s complete board members history, request access »

Calixar Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Calixar Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Banque Populaire Lender/Debt Provider Minority 000 0000 000000 0
Bpifrance Sovereign Wealth Fund Minority 000 0000 000000 0
Siparex XAnge Venture Venture Capital Minority 000 0000 000000 0
Grenoble Angels Angel Group Minority 000 0000 000000 0
Health-angels Rhone-alpes Angel Group Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »